Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA-Irinotecan + Cetuximab in 2nd line mCRC (Chime)
NCT02216487Phase 2Unknown
- Sponsor
- Western General Hospital
- Start
- Jun 2014
- Primary completion
- Jun 2016
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HyCAMP in metastatic colorectal cancer (mCRC), sponsored by Western General Hospital. Status: unknown.
02
Drugs
HyCAMP
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02216487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02216487.